Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk's Growth Opportunities Go Far Beyond Just Weight Loss and Diabetes
09:10am, Thursday, 08'th Aug 2024
GLP-1 drugs have helped people lose weight, but they can have other positive effects. A recent study found that they could help with Alzheimer's disease.
Novo Nordisk Withdraws Wegovy FDA Heart Failure Submission, Terminates Development Of Two Early Stage Assets
01:55pm, Wednesday, 07'th Aug 2024
Earlier on Wednesday, Denmark's most valuable company, Novo Nordisk A/S NVO, reported second-quarter earnings that missed the analyst consensus.
Market Misses: ABNB, NVO, LYFT & RIVN
12:27pm, Wednesday, 07'th Aug 2024
Despite a positive first half to Wednesday's trading day, a few notable stocks fell when earnings didn't meet expectations. Caroline Woods joins Oliver Renick to take a closer look at Airbnb (ABNB), N
Why Shares of Wegovy Maker Novo Nordisk Are Tumbling Today
12:23pm, Wednesday, 07'th Aug 2024
Sales of weight-loss drug Wegovy and type 2 diabetes therapy Ozempic both missed expectations. A combination of supply shortages and competition are proving to be unexpected hurdles.
NVO Stock Alert: Why Is Novo Nordisk Down 8% Today?
12:21pm, Wednesday, 07'th Aug 2024
Novo Nordisk (NYSE:NVO) stock is falling on Wednesday after the pharmaceutical company announced results for the second quarter of 2024. A major blow to the company comes from its revenue of $3.8 bill
Novo Nordisk A/S (NVO) Q2 2024 Earnings Call Transcript
11:41am, Wednesday, 07'th Aug 2024
Novo Nordisk A/S (NVO) Q2 2024 Earnings Conference Call August 7, 2024 7:00 AM ET Company Participants Jacob Martin Wiborg Rode - Head of Investor Relations Lars Fruergaard Jørgensen - Chief Executiv
Novo Nordisk is scaling Wegovy supply 'significantly': CFO
11:30am, Wednesday, 07'th Aug 2024
Novo Nordisk (NVO) shares are falling in Wednesday's pre-market session — and into the regular trading session — after the pharmaceutical giant missed second quarter revenue estimates ($3.8 billio
Novo Nordisk Dives On Rare Miss As Pricing Pressure Weighs On Ozempic, Wegovy
09:56am, Wednesday, 07'th Aug 2024
Novo Nordisk stock tumbled Wednesday after the drugmaker reported a rare sales miss for its two biggest moneymakers, Ozempic and Wegovy.
Novo Nordisk Slides as Weight-Loss Drugs Fuel Less Growth Than Expected
09:21am, Wednesday, 07'th Aug 2024
Novo Nordisk's (NVO) American depositary receipts (ADRs) slipped in pre-market trading Wednesday morning after rising sales of the company's weight-loss drugs failed to boost earnings to the level of
'Attractive' growth ahead for Novo Nordisk, CEO says
09:15am, Wednesday, 07'th Aug 2024
Novo Nordisk CEO Lars Fruergaard Jørgensen discusses the pharmaceutical company's second-quarter earnings.
Novo Nordisk: Growth Only Limited By Manufacturing Capacity
09:06am, Wednesday, 07'th Aug 2024
Novo has helped to create a new market that should provide over 20% growth in the medium term. Three additional drivers for Novo include increasing obesity treatment capacity, insurance coverage, and
Novo Nordisk (NVO) Falls as Q2 Earnings and Sales Miss, View Up
09:05am, Wednesday, 07'th Aug 2024
Novo Nordisk (NVO) falls as it reports lower-than-expected Q2 results, missing both earnings and revenue estimates. However, sales of Diabetes and Obesity care products increase year over year.
US patients staying on Wegovy obesity drug for 'around six months', Novo Nordisk says
08:21am, Wednesday, 07'th Aug 2024
U.S. patients are staying on Novo Nordisk's Wegovy weight-loss medication for "around six months", an executive said on Wednesday, adding that the company is confident that over time as shortages ease
Novo Nordisk's Wegovy miss 'will likely raise questions', says investment bank
07:08am, Wednesday, 07'th Aug 2024
Ozempic maker Novo Nordisk's (NYSE:NVO) weightloss drug sales were below expectations in the second quarter but this is not a significant concern, analysts said. Sales of Wegovy, the brand for sema
Is It Too Late to Buy Novo Nordisk Stock After Its 57% Surge?
06:40am, Wednesday, 07'th Aug 2024
Novo Nordisk is the leader in the glucagon-like peptide 1 (GLP-1) agonists market with 70% share. The company has notched some big wins with Wegovy this year, opening up several new billion-dollar mar
